Affiliation: Tufts-New England Medical Center
- Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failurePaul J Hauptman
Division of Cardiology, Saint Louis University School of Medicine, St. Louis, Missouri, USA
Am J Cardiol 98:60L-66L. 2006..The background, methods, and statistical approaches used in this trial are reviewed in this article...
- The historical and conceptual evolution of radionuclide assessment of myocardial viabilityJames E Udelson
Division of Cardiology, Tufts-New England Medical Center, Boston, MA 02111, USA
J Nucl Cardiol 11:318-34. 2004
- Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imagingJames E Udelson
Division of Cardiology, Tufts New England Medical Center, 750 Washington St, Boston, Mass 02111, USA
Circulation 109:457-64. 2004..Selective agonism of the adenosine A2A receptor should result in a similar degree of coronary vasodilation (and thus similar perfusion images) with fewer side effects...
- Ventricular remodeling in heart failure and the effect of beta-blockadeJames E Udelson
Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
Am J Cardiol 93:43B-8B. 2004..Differences in their effect on remodeling have been recently shown among the beta-blockers. Several studies and a meta-analysis suggest that carvedilol may be more favorable to outcome, having the most effect on LV remodeling...
- Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunctionJames E Udelson
Division of Cardiology, Tufts New England Medical Center Tufts University School of Medicine, Boston, Massachusetts 02111, USA
J Am Coll Cardiol 49:2151-9. 2007..This study sought to examine the effects of vasopressin V2 receptor antagonism with tolvaptan on the changes in left ventricular (LV) volumes over time...
- Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremiaMihai Gheorghiade
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
Am J Cardiol 97:1064-7. 2006..No differences in adverse events were observed between the groups. In conclusion, tolvaptan appears to be more effective than fluid restriction at correcting hyponatremia in hospitalized subjects, without an increase in adverse events...
- Overview of vasopressin receptor antagonists in heart failure resulting in hospitalizationLeonardo De Luca
Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy
Am J Cardiol 96:24L-33L. 2005..Some AVP receptor antagonists have shown promising results in animal studies and small-scale clinical trials. The purpose of this review was to update the current status of studies with the available AVP antagonists...
- Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathyIacopo Olivotto
Regional Referral Center for Myocardial Diseases and Radiology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
J Am Coll Cardiol 52:559-66. 2008..Our aim was to assess the distribution and clinical significance of left ventricular (LV) mass in patients with hypertrophic cardiomyopathy (HCM)...
- Gender-based differences in brachial artery flow-mediated vasodilation as an indicator of significant coronary artery diseaseAyan R Patel
The Division of Cardiology, Department of Medicine, Tufts New England Medical Center, Boston, Massachusetts, USA
Am J Cardiol 96:1223-6. 2005..In studies using FMD to evaluate cardiovascular risk, different standards should be applied for women and men...
- Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathyCaitlin J Harrigan
PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical School, Boston, MA, USA
Am J Cardiol 101:668-73. 2008..The identification of accessory PMs may be useful in planning preoperative strategy...
- Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathyIacopo Olivotto
Regional Referral Center for Myocardial Diseases, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
J Am Coll Cardiol 46:480-7. 2005..The goal of this study was to assess gender-related differences in a multicenter population with hypertrophic cardiomyopathy (HCM)...
- Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathyMartin S Maron
Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
Am J Cardiol 95:1329-33. 2005..In conclusion, no direct relation was evident between symptoms of heart failure and magnitude of LV wall thickness, with implications for the natural history of HC...
- Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathyKevin M Harris
Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 60, Minneapolis, Minnesota 55407, USA
Circulation 114:216-25. 2006..ES is an unfavorable complication (mortality rate 11% per year) and a sudden death risk factor; it requires vigilance to permit timely recognition and the necessity for defibrillator implantation and heart transplantation...
- Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fractionNorman C Wang
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
JAMA 299:2656-66. 2008..Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied...
- Right ventricular involvement in hypertrophic cardiomyopathyMartin S Maron
Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts New England Medical Center, Boston, MA, USA
Am J Cardiol 100:1293-8. 2007..4, p <0.001). Only 1 (2%) patient with HC had evidence of RV wall fibrosis. In conclusion, morphologic RV abnormalities are present in a substantial proportion of patients with HC...
- Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trialJoseph Rossi
Feinberg School of Medicine Northwestern University, Chicago, Illinois 60611, USA
Acute Card Care 9:82-6. 2007..Hyponatremia predicts poor outcome in patients with acute heart failure syndromes. This study evaluated the relationship between baseline serum sodium, change in serum sodium, and 60-day mortality in hospitalized heart failure patients...
- Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trialDouglas W Losordo
Feinberg Cardiovascular Research Institute, and Department of Medicine, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL 60611, USA
Circulation 115:3165-72. 2007..Preclinical studies have indicated that human CD34+ stem cells induce neovascularization in ischemic myocardium, which enhances perfusion and function...
- Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathyMartin S Maron
Division of Cardiology, Hypertrophic Cardiomyopathy Center, Tufts Medical Center, Boston, Massachussetts 02111, USA
Circulation 118:1541-9. 2008..This study reports the prevalence, morphology, clinical course, and management of an underrecognized subgroup of HCM patients with left ventricular apical aneurysms...
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status TrialsMihai Gheorghiade
Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
JAMA 297:1332-43. 2007..Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition...
- Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam
Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
JAMA 297:1319-31. 2007..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
- Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery diseasePrem Soman
Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
J Nucl Cardiol 13:756-60. 2006..Recent evidence suggests that coronary endothelial dysfunction might play a role in the pathogenesis of these defects...
- Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstructionMartin S Maron
Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
Circulation 114:2232-9. 2006..We sought to prospectively define the prevalence, clinical profile, and significance of left ventricular (LV) outflow tract obstruction under resting conditions and with physiological exercise in a large HCM cohort...
- Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)Mihai Gheorghiade
Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
J Card Fail 11:260-9. 2005..The results of EVEREST will determine whether these effects translate into improved clinical outcomes...
- Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heartRichard D Patten
Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
J Am Coll Cardiol 45:1419-24. 2005..We examined the effect of mechanical unloading with ventricular assist device (VAD) therapy on myocardial inducible nitric oxide synthase (iNOS) expression and cardiomyocyte apoptosis in patients with end-stage heart failure (HF)...
- Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trialMichael Simons
Section of Cardiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
Circulation 105:788-93. 2002..We conducted the FGF Initiating RevaScularization Trial (FIRST) to evaluate further the efficacy and safety of recombinant FGF2 (rFGF2)...
- Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysisKevin C Allman
Concord Hospital, Concord NSW, Australia
J Am Coll Cardiol 39:1151-8. 2002....
- Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trialsInder S Anand
Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
J Card Fail 8:S452-64. 2002..CONCLUSIONS: Each of these techniques carries specific advantages and disadvantages for assessment of remodeling in individual patients and in the context of large-scale clinical trials...
- Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunctionJames E Udelson
Division of Cardiology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
J Card Fail 8:S465-71. 2002....
- New concepts in post-infarction ventricular remodelingJames E Udelson
Division of Cardiology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
Rev Cardiovasc Med 4:S3-12. 2003..It is also demonstrated that drug therapies that slow or reverse the remodeling process appear to have favorable natural history effects in the short term as well as during long-term therapy...
- Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipientsAyan R Patel
Division of Cardiology/Department of Medicine, Molecular Cardiology Research Institute, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA
Am J Cardiol 91:897-9. 2003
- Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitudeJeffrey T Kuvin
Department of Medicine, Division of Cardiology, Tufts New England Medical Center Hospitals, Tufts University School of Medicine, Boston, MA 02111, USA
Am Heart J 146:168-74. 2003..We evaluated the relationship between changes in PWA of the finger and peripheral endothelial function...
- Quantitative instruments for predicting risk ... and benefitJames E Udelson
J Am Coll Cardiol 45:730-2. 2005
- Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trialCarey Kimmelstiel
Division of Cardiology, Tufts-New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
Circulation 110:1450-5. 2004..Longer-term benefit likely requires more active chronic intervention, even among patients who appear clinically stable...
- A head-to-head comparison of infusion and bolus doses of adenosine for stress myocardial contrast echocardiographyHans Joachim Nesser
IInd Department of Medicine, Cardiology, KH der Elisabethinen Hospital, Linz, Austria
Echocardiography 23:483-9. 2006..This study was a head-to-head, intraindividual comparison of the diagnostic accuracy and side effect profile of bolus and infusion administration of adenosine for stress myocardial contrast echocardiography (MCE)...
- Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trialJames E Udelson
Division of Clinical Care Research, Tufts New England Medical Center, 750 Washington St, Box 70, Boston, MA 02111, USA
JAMA 288:2693-700. 2002....
- Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for managementJames E Udelson
Division of Cardiology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Mass 02111, USA
J Nucl Cardiol 9:40S-52S. 2002
- Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemiaVasken Dilsizian
Division of Nuclear Medicine, University of Maryland Hospital and School of Medicine, Baltimore, MD 21201 1595, USA
Circulation 112:2169-74. 2005..We hypothesized that a branched-chain fatty acid, beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid (BMIPP), might identify the presence of myocardial ischemia late after demand ischemia at rest up to 30 hours later...
- Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonanceA Selcuk Adabag
Division of Cardiology, Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA
J Am Coll Cardiol 51:1369-74. 2008..Our aim was to determine whether myocardial fibrosis, detected by cardiovascular magnetic resonance (CMR), represents an arrhythmogenic substrate in hypertrophic cardiomyopathy (HCM)...
- Arginine vasopressin antagonists for the treatment of heart failure and hyponatremiaJohn J Finley
Division of Cardiology and Department of Medicine, Tufts Medical Center, Boston, Mass. 02111, USA
Circulation 118:410-21. 2008
- Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndromeBarry J Maron
J Am Coll Cardiol 45:1340-5. 2005
- Assessment and key targets for therapy in the post-myocardial infarction patient with left ventricular dysfunctionJames D Flaherty
Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Am J Cardiol 102:5G-12G. 2008..This review describes the current modalities for assessing the key pathophysiologic targets in post-MI patients with LVD and the effects of systemic factors on cardiac disease severity...
- Prevention and reversal of left ventricular remodeling: summationMarvin A Konstam
Department of Medicine, Division of Cardiology, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
J Card Fail 8:S506-11. 2002
- Future directions of myocardial fatty acid imagingChristopher J Pastore
Division of Cardiology, Department of Medicine, Tufts-New England Medical Center, Boston, MA 02111, USA
J Nucl Cardiol 14:S153-63. 2007
- Screening the population for coronary artery disease: is it like screening for cancer?Prem Soman
J Nucl Cardiol 12:145-7. 2005
- ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 GuideliFrancis J Klocke
Circulation 108:1404-18. 2003
- Ventricular remodeling in heart failure: a credible surrogate endpointMarvin A Konstam
J Card Fail 9:350-3. 2003
- Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathyBarry J Maron
The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 60, Minneapolis, Minn 55407, USA
Circulation 107:2872-5. 2003
- MIBG imaging for selecting heart failure patients for defibrillator therapy: a first stepColin D Shafer
J Nucl Cardiol 10:208-10. 2003
- Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunctionGregg C Fonarow
Rev Cardiovasc Med 4:S54-9. 2003
- The price for probability: Comparing the costs of diagnostic testing strategiesPrem Soman
J Nucl Cardiol 14:142-4. 2007
- Hyponatremia in patients with heart failureLeonardo De Luca
Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy
Am J Cardiol 96:19L-23L. 2005..Recent studies have suggested that correction of hyponatremia may be associated with improved survival. This hypothesis is currently being studied in large prospective randomized clinical trials...
- Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failureOlaf Hedrich
Tufts-New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
Heart Fail Clin 1:103-27. 2005
- LV Function Assessment Core Lab for IMMEDIATE TrialJames Udelson; Fiscal Year: 2006..These data Will provide robust information with sufficient power to test the concepts in Hypothesis H9 of the parent trial and provide substantial insights into the mechanism of GIK effect. ..
- Myocardial Viability and Remodeling in the OATJames Udelson; Fiscal Year: 2007..OAT-NUC is the only viability ancillary study of OAT, and thus serves a critical need in assessing potential mechanisms of the findings in OAT. ..